[New insights of vitamin D-based therapy for prostate cancer]

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• Prostate cancer is a leading cause of cancer death in men.
• Current treatments like hormone therapy and chemotherapy often lead to resistance.
• Vitamin D deficiency is linked to increased prostate cancer severity, but its mechanisms are unclear.

Purpose of the Study:

• To investigate the therapeutic potential of vitamin D analogs in prostate cancer.
• To explore the effects of vitamin D analogs on the tumor microenvironment.
• To assess the efficacy of vitamin D analogs in overcoming chemoresistance.

Main Methods:

• Utilized Pten^(i)pe-/- mice, a model for prostate cancer.
• Administered a vitamin D analog to mice to evaluate effects on the tumor microenvironment.
• Combined a vitamin D analog with docetaxel to treat prostate cancer spheroids and patient-derived xenografts.

Main Results:

• Vitamin D analog demonstrated therapeutic effects on the tumor microenvironment in a mouse model.
• Combination therapy with a vitamin D analog and docetaxel overcame chemoresistance in patient-derived models.
• The combination therapy was effective in prostate cancer models resistant to docetaxel and androgen deprivation.

Conclusions:

• Vitamin D analogs exhibit anticancer effects in prostate cancer.
• Combining vitamin D analogs with chemotherapy can overcome treatment resistance.
• Vitamin D analog-based therapies represent a promising new strategy for advanced prostate cancer management.